Clinical applications of anticancer drugs targeted to topoisomerase II.
Agents which 'poison' the enzyme topoisomerase II, have proven to be useful drugs for cancer treatment. Six antineoplastic drugs, which target topoisomerase II (doxorubicin, daunorubicin, idarubicin, mitoxantrone, etoposide and teniposide) are currently approved for clinical use in the United States. In this paper, the strategies and goals of cancer chemotherapy are summarized for the non-clinician. The use, pharmacology and toxicity of each of the six currently approved topoisomerase II inhibiting agents are reviewed.
Hande
K R
KR
Department of Medicine and Pharmacology, Vanderbilt University School of Medicine, Nashville, TN 37232-5536, USA.
D000903:Antibiotics, Antineoplastic / Q000494:pharmacology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D008942:Mitoxantrone / Q000494:pharmacology / Q000627:therapeutic use; D015394:Molecular Structure; D011034:Podophyllotoxin / Q000494:pharmacology / Q000627:therapeutic use; D059005:Topoisomerase II Inhibitors
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D059005:Topoisomerase II Inhibitors; D008942:Mitoxantrone; D011034:Podophyllotoxin